Clinical observation and management of COVID-19 patients.
Identifieur interne : 000823 ( Main/Exploration ); précédent : 000822; suivant : 000824Clinical observation and management of COVID-19 patients.
Auteurs : Taisheng Li [République populaire de Chine] ; Hongzhou Lu [République populaire de Chine] ; Wenhong Zhang [République populaire de Chine]Source :
- Emerging microbes & infections [ 2222-1751 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Chine, Essais cliniques comme sujet, Femelle, Gestion des soins aux patients, Glucocorticoïdes (usage thérapeutique), Humains, Infections à coronavirus (), Infections à coronavirus (mortalité), Infections à coronavirus (physiopathologie), Infections à coronavirus (traitement médicamenteux), Maladie grave, Mâle, Médecine traditionnelle chinoise, Pandémies, Pneumopathie virale (), Pneumopathie virale (mortalité), Pneumopathie virale (physiopathologie), Pneumopathie virale (traitement médicamenteux), Thrombophilie (), Thrombophilie (physiopathologie), Équipe soignante, Évolution de la maladie.
- MESH :
- mortalité : Infections à coronavirus, Pneumopathie virale.
- physiopathologie : Infections à coronavirus, Pneumopathie virale, Thrombophilie.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Glucocorticoïdes.
- Chine, Essais cliniques comme sujet, Femelle, Gestion des soins aux patients, Humains, Infections à coronavirus, Maladie grave, Mâle, Médecine traditionnelle chinoise, Pandémies, Pneumopathie virale, Thrombophilie, Équipe soignante, Évolution de la maladie.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Betacoronavirus, China, Clinical Trials as Topic, Coronavirus Infections (drug therapy), Coronavirus Infections (mortality), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Critical Illness, Disease Progression, Female, Glucocorticoids (therapeutic use), Humans, Male, Medicine, Chinese Traditional, Pandemics, Patient Care Management, Patient Care Team, Pneumonia, Viral (drug therapy), Pneumonia, Viral (mortality), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Thrombophilia (physiopathology), Thrombophilia (therapy).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Glucocorticoids.
- geographic : China.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- physiopathology : Coronavirus Infections, Pneumonia, Viral, Thrombophilia.
- therapy : Coronavirus Infections, Pneumonia, Viral, Thrombophilia.
- Betacoronavirus, Clinical Trials as Topic, Critical Illness, Disease Progression, Female, Humans, Male, Medicine, Chinese Traditional, Pandemics, Patient Care Management, Patient Care Team.
Abstract
Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient.
DOI: 10.1080/22221751.2020.1741327
PubMed: 32208840
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000523
- to stream PubMed, to step Curation: 000523
- to stream PubMed, to step Checkpoint: 000651
- to stream Ncbi, to step Merge: 003504
- to stream Ncbi, to step Curation: 003504
- to stream Ncbi, to step Checkpoint: 003504
- to stream Main, to step Merge: 000823
- to stream Main, to step Curation: 000823
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical observation and management of COVID-19 patients.</title><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name><affiliation wicri:level="1"><nlm:affiliation>Shanghai Public Health Clinical Center, Shanghai, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai Public Health Clinical Center, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Wenhong" sort="Zhang, Wenhong" uniqKey="Zhang W" first="Wenhong" last="Zhang">Wenhong Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32208840</idno><idno type="pmid">32208840</idno><idno type="doi">10.1080/22221751.2020.1741327</idno><idno type="wicri:Area/PubMed/Corpus">000523</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000523</idno><idno type="wicri:Area/PubMed/Curation">000523</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000523</idno><idno type="wicri:Area/PubMed/Checkpoint">000651</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000651</idno><idno type="wicri:Area/Ncbi/Merge">003504</idno><idno type="wicri:Area/Ncbi/Curation">003504</idno><idno type="wicri:Area/Ncbi/Checkpoint">003504</idno><idno type="wicri:Area/Main/Merge">000823</idno><idno type="wicri:Area/Main/Curation">000823</idno><idno type="wicri:Area/Main/Exploration">000823</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical observation and management of COVID-19 patients.</title><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name><affiliation wicri:level="1"><nlm:affiliation>Shanghai Public Health Clinical Center, Shanghai, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai Public Health Clinical Center, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Wenhong" sort="Zhang, Wenhong" uniqKey="Zhang W" first="Wenhong" last="Zhang">Wenhong Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></analytic><series><title level="j">Emerging microbes & infections</title><idno type="eISSN">2222-1751</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus</term><term>China</term><term>Clinical Trials as Topic</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (physiopathology)</term><term>Coronavirus Infections (therapy)</term><term>Critical Illness</term><term>Disease Progression</term><term>Female</term><term>Glucocorticoids (therapeutic use)</term><term>Humans</term><term>Male</term><term>Medicine, Chinese Traditional</term><term>Pandemics</term><term>Patient Care Management</term><term>Patient Care Team</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (mortality)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pneumonia, Viral (therapy)</term><term>Thrombophilia (physiopathology)</term><term>Thrombophilia (therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Chine</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Gestion des soins aux patients</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (mortalité)</term><term>Infections à coronavirus (physiopathologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Maladie grave</term><term>Mâle</term><term>Médecine traditionnelle chinoise</term><term>Pandémies</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (mortalité)</term><term>Pneumopathie virale (physiopathologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Thrombophilie ()</term><term>Thrombophilie (physiopathologie)</term><term>Équipe soignante</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Glucocorticoids</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Thrombophilie</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Glucocorticoïdes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Clinical Trials as Topic</term><term>Critical Illness</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Medicine, Chinese Traditional</term><term>Pandemics</term><term>Patient Care Management</term><term>Patient Care Team</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Chine</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Gestion des soins aux patients</term><term>Humains</term><term>Infections à coronavirus</term><term>Maladie grave</term><term>Mâle</term><term>Médecine traditionnelle chinoise</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Thrombophilie</term><term>Équipe soignante</term><term>Évolution de la maladie</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><settlement><li>Pékin</li></settlement></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name></noRegion><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name><name sortKey="Zhang, Wenhong" sort="Zhang, Wenhong" uniqKey="Zhang W" first="Wenhong" last="Zhang">Wenhong Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000823 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000823 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32208840
|texte= Clinical observation and management of COVID-19 patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32208840" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |